➡️ nejm.org/doi/full/10.10…

#TumorBoardTuesday Brian Rini, MD Integrity CE, LLC #TumorBoardTuesday #OncTwitter 70 yo 👩🏻‍🦳, F , ECOG 1, with recurrent RCC to Nx bed, 🫁 and LN with early-PD after Pembro/axi, and recent PD on tivozanib after 18 mo.

From the NEJM Archive: Retropubic Prostatectomy (Original Article, July 8, 1948) nej.md/4kj4RIA

Nice work from Monda et al documenting >5x 📉↘️ surgical overtreatment of low risk prostate cancer in SEER-Medicare & MUSIC Urology ✅uncoupling dx from rx ✅reframes context of benefit/harm assoc w PSA screening 👀➡️ jamanetwork.com/journals/jamao…

➡️After 30 years of follow-up, radical prostatectomy significantly reduced prostate cancer mortality vs. watchful waiting in early disease (ARR: 17%, NNT: 6). 🎯Benefits of RP increase over time, lifelong impact. OncoAlert Yüksel Ürün Advanced Prostate Cancer Consensus Conference Dra. María Natalia Gandur Quiroga Bárbara Melão, MD, PhD

Miguel Zugman presented interesting results #KCRS 2025 -- cabo seems equivalent to TKI/IO. Since there seems no immunologic synergy in the long-term f/u studies in RCC and other cancers, our patients deserve randomized data. with SAMETA and STELLAR closed please consider PAPMET2!

IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks outcomes in the ctDNA-ve, supporting a ctDNA adjusted approach. It’s been a long journey for atezo in UC but it has +ve OS at last natera.com/company/news/i…

Excited to share our new paper European Urology Oncology! 🎉 We developed patient-centered, stage-specific FKSI-23 tools to better capture HRQOL in localized & metastatic RCC, moving beyond generic instruments to what truly matters to patients Tom Powles Sumanta K. Pal, MD, FASCO sciencedirect.com/science/articl…

🔬 Cures don’t happen overnight — each discovery builds on years of work until a breakthrough. Since 1995, KCA has funded $7M+ in research. Follow our #ResearchMatters 🧵to see the impact on kidney cancer care + patient outcomes: kidneycancer.org/research-matte…

Kidney injury molecule (KIM-1) is a strongly prognostic circulating biomarker & represents molecular residual disease in renal cancer. It potentially identifies responders to immunotherapy like ctDNA in bladder cancer. It is described for the 1st time in RCC in Annals of Oncology

1/ Now out in Annals of Oncology! In patients with kidney cancer, a blood test for KIM-1 is prognostic and predictive for adjuvant immunotherapy. Amazing multi-institution collaboration Sumanta K. Pal, MD, FASCO Brian Rini, MD Laurence Albiges Robert Uzzo Genentech Romain Banchereau doi.org/10.1016/j.anno…

PRIME trial: Biparametric MRI (no contrast) caught significant prostate cancer as well as full multiparametric scans. Shorter, cheaper, safer, could reset the standard of care worldwide? #ProstateCancer #Oncology doi:10.1001/jama.2025.13722 JAMA Advanced Prostate Cancer Consensus Conference Prostate Cancer Foundation

Grateful to help write this editorial with Todd 〽️ Morgan, MD Matt Davenport Kudos to the authors! The future is now for bpMRI! Cheaper, quicker, easier for patients ✅ Similar diagnostic accuracy ✅

How fast do #rcc tumor thrombi grow? 📈 In our cohort Mayo Clinic Urology (n=141), venous tumor thrombi expanded ~1 cm/month (wide range). Faster growth seen with higher Mayo level, sarcomatoid/rhabdoid features & metastasis. These data can guide pre-op imaging & surgical triage.

ALBAN, POTOMAC & CREST #ESMO25 (atezolizumab/sasalimab/in MIBC) Annals of Oncology show a lot variability. It no easy to conclude exactly which NMIBC patients benefit from ICI therapy. There is over treatment and it’s not without toxicity Joshua Meeks

🚨 #ESMO25 Update! 5-year follow-up from CheckMate-274 shows durable benefit of adjuvant nivolumab in high-risk muscle-invasive bladder cancer 💪 🔹 DFS: 26 vs 9 mo → HR 0.66 🔹 OS: 75 vs 51 mo (nivo vs placebo) 🔹 Benefit maintained even after neoadjuvant chemo 🔹 ctDNA

A highlight from #IKCSNA25 🔬 Hearing Gordon Freeman on the PD-1/L1 story and combo successes, lots in RCC! •KN-564 🔪 • +TKI: CLEAR/CM-9ER • +CTLA-4: CM-214 & hopefully more on the way! • +oral microbial (S2419/BioFront) 🦠 • +vaccine (INTERPATH-004) 💉 • +LAG3 (?)🛡️🚫